An interventional study of Multimodal Exercise Program in Type 2 Diabetes Mellitus (T2DM) and Sarcopenia, sponsored by yueh chu wu. Recruiting at 1 site in Taiwan. Open to participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-30.
Sponsored by yueh chu wu · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 278 studies in Diabetes Mellitus, Type 2 with a site in Taiwan — 36 open to participants now, 41 under way, 14 of them phase 3. Diabetes Mellitus, Type 2 · Taiwan.
Among the 278 studies in Diabetes Mellitus, Type 2 with a site in Taiwan, this one is the 176th largest by planned enrollment of the 245 interventional ones that give a count, is one of 17 that started in 2026, is one of 57 with no phase, reaches primary completion later than 11 of the 40 other live ones, and was the 260th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →36 of the 278 studies in Diabetes Mellitus, Type 2 with a site in Taiwan are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Taiwan, United States, Argentina and 8 more countries
Ages 18+
AstraZeneca · Sites in Taiwan, United States, Argentina and 13 more countries
Ages 18+
Novo Nordisk A/S · Sites in Taiwan, United States, Argentina and 7 more countries
Ages 10–18
Eli Lilly and Company · Sites in Taiwan, United States, Belgium and 8 more countries
Ages 10–17
AstraZeneca · Sites in Taiwan, United States, Argentina and 10 more countries
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 45 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
278 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 23 · Phase 3 134 · Phase 4 31
First in 1998; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 128 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 435 across the 245 interventional studies, 1,120 across the 33 observational. Of the 207 that completed or were terminated, 124 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
185 of 278 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with yueh chu wu as lead sponsor.
yueh chu wu has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
5 of the studies in Diabetes Mellitus, Type 2 with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07609290Chimei Medical CenterEffects of Exercise Snacks on Clinical and Health Outcomes | 2026-12-31 |
| NCT07642830Chang Gung Memorial HospitalDigital Health Solutions for Patients With Type 2 Diabetes | 2027-01-04 |
| NCT07103460National Taipei University of Nursing and Health SciencesEssential Oil-Assisted Respiratory Training in Type 2 Diabetic Patients With Lung Infections | 2027-07-25 |
| NCT06278207BayerAn Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions | 2027-09-30 |
| NCT07684690National Taiwan University HospitalAI-Assisted Antidiabetic Drug Consultation System for Glycemic Control in Type 2 Diabetes Patients Managed by Non-Specialist Physicians | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 278 studies in Diabetes Mellitus, Type 2 with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate the effects of a 12-week multimodal exercise intervention on middle-aged and older adults (aged 45\~85 years) with Type 2 Diabetes Mellitus (T2DM). The program combines supervised training, home-based sessions, and digital support to improve muscle function, physical performance, metabolic control, and quality of life.
Middle-aged and older adults with T2DM, particularly in Asian populations, face a heightened risk of sarcopenia. This condition leads to a decline in muscle mass and function, negatively impacting quality of life. Effective interventions are urgently needed to slow disease progression. This randomized controlled trial will recruit 128 adults. Participants will be randomly assigned to either a control group or an intervention group. The intervention involves a multimodal exercise program and educational materials, while the control group receives standard health education. Assessments will be conducted at baseline, week 12, and week 24 to evaluate physical function, sarcopenia risk, metabolic control, and quality of life.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Limited limb or joint function that prevents exercise (e.g., recent fractures or dislocations).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
• Arm Description: Participants in this group will engage in a 12-week multimodal exercise program. The program includes supervised training sessions, home-based exercises, and digital support. They will also receive a "Diabetes and Muscle Health Handbook" to guide their training.
Behavioral: Multimodal Exercise Program
Participants in this group will serve as the control. They will receive a "Nutrition and Muscle Health Education Sheet" at the beginning of the study. They will not participate in the multimodal exercise program and will continue with their routine health management based on existing medical advice.
Participants will engage in a 12-week multimodal exercise program comprising supervised training sessions, home-based exercises, and digital support. To facilitate adherence and proper technique, participants will also receive a "Diabetes and Muscle Health Handbook" as a training guide.
Also known as: Control Group
Physical Function (5TSTS)
The Five-Times Sit-to-Stand Test (5TSTS) assesses lower limb muscle power. Participants are asked to stand up and sit down five times as quickly as possible with arms folded. The time to completion is recorded in seconds and analyzed as a continuous variable. According to the 2019 Asian Working Group for Sarcopenia (AWGS) consensus, a completion time of ≥ 12 seconds is considered abnormal and indicates low physical performance.
Time frame: Change from Baseline at Week 12 and Week 24
Handgrip Strength (HGS)
Handgrip strength (HGS) is assessed using a digital dynamometer (e.g., Jamar or an equivalent device). During the assessment, participants stand with their testing arm fully extended. Two consecutive trials are performed for each hand, and the maximum grip strength value (in kilograms) is selected for data analysis. Based on the 2019 Asian Working Group for Sarcopenia (AWGS) consensus, low muscle strength is defined as \< 28 kg for men and \< 18 kg for women
Time frame: Change from Baseline at Week 12 and Week 24
Skeletal Muscle Mass Index (SMI)
Determined by bioelectrical impedance analysis (BIA). Appendicular skeletal muscle mass (ASM, kg) is calculated as the sum of lean mass from both arms and legs. SMI is expressed as ASM divided by height squared (kg/m²). Low muscle mass is defined according to AWGS 2019 cut-off values (\<7.0 kg/m² for men and \<5.7 kg/m² for women).
Time frame: Change from Baseline at Week 12 and Week 24
Sarcopenia Risk: Assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs, and Falls (SARC-F) questionnaire combined with calf circumference measurement (SARC-CalF).
Assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs, and Falls (SARC-F) questionnaire combined with calf circumference measurement (SARC-CalF). The SARC-F assesses 5 items scored 0-10. A calf circumference ≤34 cm (men) or ≤33 cm (women) adds 10 points. Total SARC-CalF scores range from 0 to 20. Higher scores indicate a higher risk of sarcopenia (a worse outcome). A total SARC-CalF score ≥11 indicates a high risk.
Time frame: Change from Baseline at Week 12 and Week 24
Glycated Hemoglobin (HbA1c)
Metabolic control is evaluated by HbA1c levels. Venous blood samples are collected after an overnight fast and analyzed using standardized high-performance liquid chromatography (HPLC). Values are reported as percentages. According to the American Diabetes Association (ADA) guidelines, the target HbA1c level for patients with type 2 diabetes mellitus (T2DM) is \< 7.0%.
Time frame: Change from Baseline at Week 12 and Week 24
Quality of Life (SF-12)
Assessed using the 12-Item Short Form Health Survey (SF-12). The survey covers eight domains summarized into two composite scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Scores range from 0 to 100, with higher scores indicating better quality of life.
Time frame: Change from Baseline at Week 12 and Week 24
Plan to share: No
Started Feb 2026 (actual). Primary completion is estimated for May 2026, 2 months after the start.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 2 months is below that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.